News | October 31, 2025
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Inclacumab was generally well tolerated in THRIVE-131
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Genomics is transforming the future of modern medicine and treatment modalities across specialties
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Subscribe To Our Newsletter & Stay Updated
